Table 1.

Characteristics of FMCHP patients with and without ONS, restricted to patients with indication for ONS use

Variable	ONS Received (n=276)	No ONS Received (n=194)	P Value
Sex			0.49
Female	54.0	57.2
Male	46.0	42.8
Race			0.83
Black	44.2	45.4
White	48.9	49.0
Other	6.5	5.7
Ethnicity			0.71
Hispanic	24.3	25.8
Non-Hispanic	75.7	74.2
Diabetes as a comorbidity			0.83
Diabetes	81.2	82.0
No diabetes	18.8	18.0
Vascular access			0.38
Catheter	18.5	18.6
Arteriovenous graft	39.5	34.5
Arteriovenous fistula	39.9	42.3
Missing	2.2	4.6
FMCHP risk score categorya			0.02
Low (1–10)	10.9	10.8
Medium (11–29)	50.4	41.2
High (>29)	33.3	34.5
Missing	5.4	13.4
Age at enrollment (yr)b	60.3±13.5	59.8±13.6	0.67
Baseline serum albuminb,c	3.5 (0.2)	3.5 (0.3)	0.40
Years since ESRD onset at enrollmenta,d	2.7 (1.0–5.3)	2.8 (1.1–5.3)	0.49
Months enrolled in demonstrationd	13.5 (6.0–23.0)	9.0 (5.0–20.0)	<0.01

Data are shown as percentages, mean ± SD, or median (interquartile range). FMCHP, Fresenius Medical Care Health Plan; ONS, oral nutritional supplements.

^aThe primary data source for date of ESRD onset is the date of first dialysis as recorded by FMCHP.

^bData are shown as mean ± SD.

^cBaseline serum albumin is the average serum albumin in the first 2 months of enrollment.

^dData are shown as median (interquartile).